Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying advanced non-small cell lung cancer NSCLC with a specific KRAS G12C gene mutation to see if adding the drug LY3537982 olomorasib to standard anti-cancer treatments provides better outcomes than standard treatment alone. This Phase 3 trial evaluates different combinations including pembrolizumab with or without chemotherapy. The study is sponsored by Eli Lilly and Company and aims to improve first-line treatment options for people with this type of lung cancer. Participants receive LY3537982 orally along with pembrolizumab intravenously in 21-day cycles. Some groups also receive chemotherapy drugs like pemetrexed and platinum agents cisplatin or carboplatin. There are various study parts including dose optimization, safety lead-in, and randomized treatment arms comparing LY3537982 combinations to placebo with pembrolizumab, with or without chemotherapy. Treatment continues until certain discontinuation criteria are met. During the study, participants will have regular visits for assessments including tumor measurements, physical function, symptom questionnaires, and safety monitoring. Researchers will measure progression-free survival, treatment side effects, response rates, and quality of life over an estimated period of up to three years depending on individual progress. Participants will be closely monitored throughout to evaluate the effects and safety of the study drug combinations.
Actively Recruiting
Researchers are evaluating whether olomorasib combined with immunotherapy is more effective than standard immunotherapy alone for people with KRAS G12C-mutant non-small cell lung cancer NSCLC. The study has two parts Part A focuses on participants with resected NSCLC treated with pembrolizumab, and Part B includes participants with unresectable NSCLC treated with durvalumab. This Phase 3 study aims to assess disease control and survival outcomes over several years. Participants will be randomly assigned to receive either olomorasib or a placebo, both given orally, combined with intravenous pembrolizumab or durvalumab depending on the study part. Treatment with the combination lasts for up to 1 year, followed by olomorasib or placebo alone for up to 3 years. The study involves parallel groups comparing these combinations in participants with either resected or unresectable disease. During the study, participants will have regular assessments including disease monitoring for progression or recurrence, quality of life questionnaires, and evaluations of lung cancer symptoms. Researchers will track outcomes such as disease-free survival in Part A and progression-free survival in Part B, along with overall survival and symptom changes. The total participation may last about 3 years, with ongoing follow-up to monitor safety and treatment effects.